These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 36528237

  • 1. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, Biegel H, Kowdley KV, Chalasani N, Dasarathy S, Diehl AM, Loomba R, Hameed B, Behling C, Kleiner DE, Karpen SJ, Williams J, Jia Y, Yates KP, Tonascia J.
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [Abstract] [Full Text] [Related]

  • 2. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic Steatohepatitis Clinical Research Network.
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [Abstract] [Full Text] [Related]

  • 3. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R, Mullish BH, Giannakeas N, Maurice JB, Angkathunyakul N, Lloyd J, Tzallas AT, Tsipouras M, Yee M, Thursz MR, Goldin RD, Manousou P.
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [Abstract] [Full Text] [Related]

  • 4. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V, LIDO (Liver Injury in Diabetes and Obesity) Study Group.
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [Abstract] [Full Text] [Related]

  • 5. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S.
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [Abstract] [Full Text] [Related]

  • 6. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M, HEPAmet Registry.
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [Abstract] [Full Text] [Related]

  • 7. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [Abstract] [Full Text] [Related]

  • 8. Training of computational algorithms to predict NAFLD activity score and fibrosis stage from liver histopathology slides.
    Qu H, Minacapelli CD, Tait C, Gupta K, Bhurwal A, Catalano C, Dafalla R, Metaxas D, Rustgi VK.
    Comput Methods Programs Biomed; 2021 Aug; 207():106153. PubMed ID: 34020377
    [Abstract] [Full Text] [Related]

  • 9. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos SA, Deng Y, Kokkorakis M, Agraz M, Mylonakis SC, Katsarou A, Verrastro O, Markakis G, Eslam M, Papatheodoridis G, George J, Mingrone G, Mantzoros CS.
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [Abstract] [Full Text] [Related]

  • 10. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE, Pitts R, Lai M, Loureiro J, Masia R, Osganian SA, Gustafson JL, Hutter MM, Gee DW, Meireles OR, Witkowski ER, Richards SM, Jacob J, Finkel N, Ngo D, Wang TJ, Gerszten RE, Ukomadu C, Jennings LL.
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [Abstract] [Full Text] [Related]

  • 11. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM.
    Int J Mol Sci; 2024 Aug 02; 25(15):. PubMed ID: 39126031
    [Abstract] [Full Text] [Related]

  • 12. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA, Minnich A, Sanyal AJ, Loomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED.
    JHEP Rep; 2023 Apr 02; 5(4):100661. PubMed ID: 36866389
    [Abstract] [Full Text] [Related]

  • 13. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP, Hernández-Rocha C, Morales C, Vargas JI, Solís N, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M.
    Gastroenterol Hepatol; 2017 Apr 02; 40(6):388-394. PubMed ID: 28359548
    [Abstract] [Full Text] [Related]

  • 14. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
    Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, Bedossa P, Geier A, Francque S, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison SA, Chen Y, Cobbold JF, Pavlides M, Holleboom AG, Yki-Jarvinen H, Crespo J, Karsdal M, Ostroff R, Zafarmand MH, Torstenson R, Duffin K, Yunis C, Brass C, Ekstedt M, Aithal GP, Schattenberg JM, Bugianesi E, Romero-Gomez M, Ratziu V, Anstee QM, Bossuyt PM, Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators.
    Lancet Gastroenterol Hepatol; 2023 Aug 02; 8(8):714-725. PubMed ID: 36958367
    [Abstract] [Full Text] [Related]

  • 15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Fukusato T.
    World J Gastroenterol; 2014 Nov 14; 20(42):15539-48. PubMed ID: 25400438
    [Abstract] [Full Text] [Related]

  • 16. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F, Barb D, Lomonaco R, Lai J, Cusi K.
    J Hepatol; 2020 Mar 14; 72(3):401-410. PubMed ID: 31589891
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L, Friedrich-Rust M, Loomba R.
    Gastroenterology; 2019 Apr 14; 156(5):1264-1281.e4. PubMed ID: 30660725
    [Abstract] [Full Text] [Related]

  • 18. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.
    Liver Int; 2019 Sep 14; 39(9):1742-1754. PubMed ID: 31169972
    [Abstract] [Full Text] [Related]

  • 19. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P, Patel J, Ingle M, Sawant P.
    Indian J Gastroenterol; 2015 May 14; 34(3):200-8. PubMed ID: 26108652
    [Abstract] [Full Text] [Related]

  • 20. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F, Goh GB, Tiniakos D, Wee A, Leow WQ, Zhao JM, Rao HY, Wang XX, Wang Q, Wan WK, Lim KH, Romero-Gomez M, Petta S, Bugianesi E, Tan CK, Harrison SA, Anstee QM, Chang PJ, Wei L.
    Hepatology; 2020 Jun 14; 71(6):1953-1966. PubMed ID: 31600834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.